ArticleFEBS open bio2022

Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain.

Xin-Yuan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.